Narang Puneet, Glowacki Anna, Lippmann Steven
Dr. Narang is Assistant Professor with the University of Minnesota and Staff Physician and Lead ECT Psychiatrist at Regions Hospital, Minneapolis-St. Paul, Minnesota; Dr. Glowacki is a first year family medicine resident at John Peter Smith hospital, Fort Worth Texas; and Dr. Lippmann is Professor of Psychiatry at University of Louisville School of Medicine, Louisville, Kentucky.
Innov Clin Neurosci. 2015 Sep-Oct;12(9-10):25-8.
Electroconvulsive therapy is an established means to improve function in a variety of psychiatric and neurologic conditions, particularly for patients who remain treatment-refractory. Parkinson's disease is a neurodegenerative disorder that sometimes does not respond well to conventional pharmacotherapies. Reports have indicated that electroconvulsive therapy may be an effective and safe treatment for those patients with Parkinson's disease who are not optimally responding to first-line treatments. Despite these reports, however, electroconvulsive therapy is not often used by clinicians in patients with treatment-resistant Parkinson's disease, perhaps due to stigma, lack of knowledge regarding its safety and efficacy, and/or inability to predict the duration of therapeutic benefit.
Our objective was to determine if the available literature on ECT supports it as a safe and effective treatment option in patients with treatment-refractory Parkinson's disease.
Motoric improvement induced by electroconvulsive therapy has been documented for decades in persons with Parkinson's disease. Efficacy and safety are reported following electroconvulsive therapy in people with Parkinson's disease who have sub-optimal response to medicines or experience the "on/off" phenomenon to L-dopa. Electroconvulsive therapy is an effective option for acute and maintenance treatment of Parkinson's disease in select patients. Inability to predict how long the beneficial effects of ECT therapy will last in patients with Parkinson's disease may be a reason why this treatment is underutilized by clinicians. More research is warranted to clarify parameters for application and duration of therapeutic benefit in individuals with difficult-to-treat Parkinson's disease.
电休克治疗是改善多种精神和神经疾病功能的既定方法,特别是对于那些仍对治疗无反应的患者。帕金森病是一种神经退行性疾病,有时对传统药物治疗反应不佳。报告表明,电休克治疗对于那些对一线治疗反应不佳的帕金森病患者可能是一种有效且安全的治疗方法。然而,尽管有这些报告,临床医生在治疗抵抗性帕金森病患者中并不经常使用电休克治疗,这可能是由于耻辱感、对其安全性和有效性缺乏了解,和/或无法预测治疗益处的持续时间。
我们的目的是确定关于电休克治疗的现有文献是否支持其作为治疗抵抗性帕金森病患者的安全有效治疗选择。
几十年来,电休克治疗在帕金森病患者中引起的运动功能改善已有记录。在对药物反应欠佳或对左旋多巴出现“开/关”现象的帕金森病患者中,电休克治疗后的疗效和安全性已有报道。电休克治疗是部分帕金森病患者急性和维持治疗的有效选择。无法预测电休克治疗对帕金森病患者的有益效果能持续多久,可能是临床医生未充分利用这种治疗方法的一个原因。需要更多研究来阐明难治性帕金森病患者的应用参数和治疗益处的持续时间。